Clinical Trial Suggests Pomegranate Molecule Has Anti-Aging Benefits3 years, 5 months ago
Posted on Oct 16, 2019, 4 p.m.
Supplementation with Urolithin A, a pomegranate metabolite is suggested to safely offer anti-aging benefits due to its impact on mitochondrial and cellular health found in the first human double blind, randomized, placebo controlled trial conducted by Amazentis and Swiss Institute of Bioinformatics. “The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans.”
“There are currently no effective solutions to treat age-related decline in muscle function other than months of exercise. This is an important first clinical validation that shows Urolithin A could be a promising solution for the management of healthy muscle function during ageing,” says Professor Roger Fielding, PhD of Tufts University.
“This positive clinical translation of Urolithin A shows its potential to play an important role in advanced nutritional approaches to improve mitochondrial health through mitophagy and biogenesis, and, as a result, cellular health in humans,” says co-author Professor Johan Auwerx, MD, PhD of Amazentis Ecole Polytechnique Fédérale de Lausanne.
As published in the journal Nature Metabolism 60 healthy but sedentary elderly participants were divided into 4 groups received either a placebo, 250, 500, or 1,000 mg dose of Urolithin A daily over the course of 28 days. Efficacy of UA was determined by examining cellular and mitochondrial health biomarkers in blood and muscle tissue; findings suggest that Urolithin A may help to slow down the aging process by improving the functioning of the mitochondria.
Urolithin A may be the only known compound that can re-establish a cell’s ability to recycle defective mitochondria, this happens naturally in younger people but with age the body loses it ability to do this causing sarcopenia and weakening of other tissues.
Urolithin A is a microflora derived metabolite of ellagitannins, and it is the lead candidate of Amazentis as an oral formulation, the company hopes to build on the promising results to bring a product to market quickly. Nestle Health Science has announced a global partnership with the company to develop products containing UA to develop opportunities in healthcare and medical nutrition.
Materials provided by:
Note: Content may be edited for style and length.
This article is not intended to provide medical diagnosis, advice, treatment, or endorsement.